Study Background and Clinical Context
Renal cell carcinoma (RCC), particularly the clear-cell subtype, remains a significant global health challenge, accounting for approximately 2-3% of adult malignancies. Advanced RCC often presents with metastases, leading to poor prognosis and limited treatment options. Historically, immunotherapy agents such as cytokines had limited efficacy, but the advent of targeted therapies, including tyrosine kinase inhibitors (TKIs) like sunitinib, revolutionized management by improving progression-free and overall survival.
Despite these advances, the need for more effective and tolerable first-line options persists. Immunotherapies targeting PD-L1 and PD-1 pathways have shown promise in various cancers, including RCC, yet their potential remains underexplored. The combination of immune checkpoint blockade with anti-angiogenic agents is hypothesized to enhance anti-tumor efficacy through synergistic mechanisms. This trial investigates benmelstobart, a novel PD-L1 inhibitor, combined with anlotinib, a multi-target TKI, as a potential superior first-line therapy for advanced RCC.
